Related references
Note: Only part of the references are listed.A Retrospective Analysis of Cytogenetic and Clinical Characteristics in Patients With Multiple Myeloma
Jingsong He et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2013)
Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups
Sikander Ailawadhi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Risk factors for multiple myeloma: A hospital-based case-control study in Northwest China
Qixia Wang et al.
CANCER EPIDEMIOLOGY (2012)
Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients
M. K. Kim et al.
ANNALS OF ONCOLOGY (2011)
The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma
K. Detweiler Short et al.
LEUKEMIA (2011)
Racial disparities in incidence and outcome in multiple myeloma: a population-based study
Adam J. Waxman et al.
BLOOD (2010)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Herve Avet-Loiseau et al.
BLOOD (2007)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma
J Schmielau et al.
LEUKEMIA & LYMPHOMA (2005)
p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation
H Chang et al.
BLOOD (2005)
Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis
T Hayashi et al.
INTERNAL MEDICINE (2003)
Share Paper
